Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Pivotal Trial Expected to Initiate in 2010 for Blinatumomab
The presentations highlighted significant areas of development across Micromet’s BiTE antibody platform and included updates on:
- BiTE antibody Blinatumomab — a rapid path to market has been identified for Acute Lymphoblastic Leukemia (ALL) with a registration trial planned to begin in 2010. Dose escalation continues in the study of blinatumomab for non-Hodgkin’s lymphoma, with final results expected to be reported at the American Society of Hematology meeting in December.
- BiTE antibody MT110 — data presented at this week’s annual meeting of the American Association for Cancer Research (AACR) demonstrated MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture and in animal models. EpCAM is a target antigen that is highly and frequently expressed on many types of solid tumors. MT110 currently is in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer.
- EGFR BiTE Antibody — pre-clinical data presented at AACR demonstrated that BiTE antibodies developed from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) (panitumumab) were highly active against KRAS-and BRAF-mutated human colorectal cancer cell lines. Recent clinical studies have shown that patients with tumor cells harboring mutations in KRAS and BRAF oncogenes do not respond to treatment with Erbitux or Vectibix. These patients make up more than 40% of colorectal cancer patients.
“Micromet has developed one of the industry’s most extensive and exciting antibody pipelines. Our BiTE antibody platform continues to gain validation in the clinic leading to the planned initiation of a pivotal trial for ALL next year,” said Micromet President and CEO
An archive of the event’s presentations is available at www.micromet-inc.com.
Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in
This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab, MT110, and its EGFR BiTE antibody. You are urged to consider statements that include the words “ongoing,” “may,” “will,” “believes,” “potential,” “expects,” “plans,” “anticipates,” “intends,” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including Bayer Schering, MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet’s Annual Report on Form 10-K for the fiscal year ended
Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Micromet, Inc.